Home
-
Executive Insights: What’s Next for Novo Nordisk?
With new CEO Maziar Mike Doustdar taking the helm, Novo Nordisk is looking to expand its obesity franchise, with an oral version of it blockbuster weight-loss drug, Wegovy (semaglutide). Will that be the key to expanding the fortunes of the company?
-
Sizing Up the Blockbuster Contenders of 2025
What new products, recently or expected to launch in 2025, show blockbuster potential, and do their prospects still remain bright? DCAT Value Chain Insights takes an inside look at the companies & bio/pharmaceuticals rising to the top of the class.
-
US, EU Detail Plan for Pharmaceutical Tariffs
The White House and European Commission have released further details on the recently agreed-to US-EU trade deal, including further details on tariffs on pharmaceuticals. What’s the bottom line for the pharma industry?
DCAT MEMBER COMPANY COMMUNITY
-
ESG Update: DCAT Member Companies in the Community
The latest ESG (environmental, social and governance) news from DCAT Member Companies on how they are making an impact globally and in their local communities. Have a ESG news announcement…
-
People on the Move
Here are the latest moves and promotions of employees from the DCAT Member Company community. To submit a request to be included in People on the Move, click here. From the…
-
ICYMI: DCAT Production to Prescription Podcast: “Headwinds or Tailwinds: Will the Biotech Sector Rebound in 2025?”
Biotech companies are an important source for innovation and product development for larger companies and are an important customer base of CDMOs/CMOs. Capital flow in the biotech sector, a key…
-
DCAT Awards Grants To Student Scientists at the 2025 Regeneron International Science & Engineering Fair
The Drug, Chemical & Associated Technologies Association (DCAT) has awarded $30,000 in grants to student scientists of four projects who participated in the Regeneron International Science & Engineering Fair (Regeneron…
